| Cellular and transcriptional dynamics of human neutrophils at steady state and upon stress E Montaldo, E Lusito, V Bianchessi, N Caronni, S Scala, L Basso-Ricci, ... Nature immunology 23 (10), 1470-1483, 2022 | 74 | 2022 |
| Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro S Bellone, E Bignotti, S Lonardi, F Ferrari, F Centritto, A Masserdotti, ... Gynecologic oncology 144 (1), 146-152, 2017 | 70 | 2017 |
| Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy L Zammataro, S Lopez, S Bellone, F Pettinella, E Bonazzoli, E Perrone, ... Proceedings of the National Academy of Sciences 116 (45), 22730-22736, 2019 | 68 | 2019 |
| A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma C Han, S Bellone, ER Siegel, G Altwerger, G Menderes, E Bonazzoli, ... Gynecologic oncology 149 (3), 585-591, 2018 | 68 | 2018 |
| SYD985, a novel duocarmycin-based HER2-targeting antibody–drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/Neu expression G Menderes, E Bonazzoli, S Bellone, J Black, F Predolini, F Pettinella, ... Clinical Cancer Research 23 (19), 5836-5845, 2017 | 61 | 2017 |
| Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors C Li, E Bonazzoli, S Bellone, J Choi, W Dong, G Menderes, G Altwerger, ... Proceedings of the National Academy of Sciences 116 (2), 619-624, 2019 | 58 | 2019 |
| SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression G Menderes, E Bonazzoli, S Bellone, J Black, G Altwerger, A Masserdotti, ... Gynecologic oncology 146 (1), 179-186, 2017 | 54 | 2017 |
| In Vitro and In Vivo Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial … G Altwerger, E Bonazzoli, S Bellone, T Egawa-Takata, G Menderes, ... Molecular cancer therapeutics 17 (5), 1003-1011, 2018 | 29 | 2018 |
| Inhibition of BET bromodomain proteins with GS-5829 and GS-626510 in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer E Bonazzoli, F Predolini, E Cocco, S Bellone, G Altwerger, G Menderes, ... Clinical Cancer Research 24 (19), 4845-4853, 2018 | 23 | 2018 |
| Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high … G Menderes, E Bonazzoli, S Bellone, G Altwerger, JD Black, K Dugan, ... Gynecologic oncology 147 (1), 145-152, 2017 | 20 | 2017 |
| Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo G Menderes, E Bonazzoli, S Bellone, JD Black, S Lopez, F Pettinella, ... Medical Oncology 34, 1-8, 2017 | 20 | 2017 |
| Effects of magnetic nanoparticles on the functional activity of human monocytes and dendritic cells M Donini, F Pettinella, G Zanella, SC Gaglio, C Laudanna, ... International Journal of Molecular Sciences 24 (2), 1358, 2023 | 4 | 2023 |
| Neutrophils inhibit γδ T cell functions in the imiquimod-induced mouse model of psoriasis S Costa, D Bevilacqua, E Caveggion, S Gasperini, E Zenaro, F Pettinella, ... Frontiers in Immunology 13, 1049079, 2022 | 4 | 2022 |
| Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small … A Adamo, C Frusteri, S Pilotto, S Caligola, L Belluomini, O Poffe, ... Oncoimmunology 12 (1), 2253644, 2023 | 3 | 2023 |
| Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors F Pettinella, B Mariotti, C Lattanzi, K Bruderek, M Donini, S Costa, ... Cell Reports Medicine, 2024 | 2 | 2024 |
| Plasmacytoid Dendritic Cell, Slan+-Monocyte and Natural Killer Cell Counts Function as Blood Cell-Based Biomarkers for Predicting Responses to Immune … F Pettinella, C Lattanzi, M Donini, E Caveggion, O Marini, G Iannoto, ... Cancers 15 (21), 5285, 2023 | 1 | 2023 |
| Remarkable in vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to the tubulin-disrupting maytansinoid DM4, in … G Altwerger, E Bonazzoli, S Bellone, T Takata, G Menderes, F Pettinella, ... Gynecologic Oncology 149, 70, 2018 | 1 | 2018 |
| Mature neutrophils with PMN-MDSC activities display a common gene signature and CD84 expression F Pettinella, B Mariotti, K Bruderek, M Donini, S Costa, O Marini, G Iannoto, ... EUROPEAN JOURNAL OF IMMUNOLOGY 52, 91-91, 2022 | | 2022 |
| Mature PMN-MDSCs from G-CSF-treated healthy donors and cancer patients share a suppressive gene signature and CD84 expression F Pettinella | | 2022 |
| Correction: Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors (Proceedings of the National … C Li, E Bonazzoli, S Bellone, J Choi, W Dong, G Menderes, G Altwerger, ... Proceedings of the National Academy of Sciences of the United States of …, 2019 | | 2019 |
